Skip to content
OpenCapital
Get started

ArriVent BioPharma, Inc. AVBP Q3 2025 earnings

Reported November 10, 2025 · Before market open

EPS-$0.83Miss by $0.05
EPS estimate-$0.78

Next report

Aug 14, 2026 (In 2 weeks)
EPS estimate-$0.98

Financials

Q3 2025

Income statement

See full
Operating income-$38.3M-58.1%
Net income-$35.0M-70.1%
EPS (diluted)-$0.83-36.1%

Balance sheet

See full
Cash & equivalents$112.7M-60.2%
Total debt$56.0K-73.7%
Total equity$305.0M+9.9%
Total assets$326.6M+11.6%

Cash flow

See full
Operating cash flow-$35.8M-119%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$748.5M-4.9%
Enterprise value$635.88M+26.0%

Returns & leverage

See full
Return on equity-52%—
Debt / equity0×0.0×
Current ratio14.9×-4.4×

Versus estimates

Diluted EPS

Q1 2026-$0.96Miss by $0.08Q4 2025-$0.78Beat by $0.09
Q3 2025-$0.83Miss by $0.05
Q2 2025-$0.90Miss by $0.20Q1 2025-$1.90Miss by $1.24Q4 2024-$0.60Beat by $0.18

Ask the moment ArriVent BioPharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ArriVent BioPharma, Inc. report Q3 2025 earnings?
ArriVent BioPharma, Inc. (AVBP) reported Q3 2025 earnings on November 10, 2025 before market open.
What were ArriVent BioPharma, Inc.'s Q3 2025 revenue and EPS?
ArriVent BioPharma, Inc. reported eps of $-0.83 for Q3 2025.
Did ArriVent BioPharma, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.78 by $0.05.
How did ArriVent BioPharma, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 36.1% from $-0.61.
Where can I find ArriVent BioPharma, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-108839) and the 10-Q periodic report (0001104659-25-108847) directly on SEC EDGAR. The filing index links above go to sec.gov.